Aurinia Pharmaceuticals annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aurinia Pharmaceuticals Stock-Based Compensation Growth & History (AUPH)
Aurinia Pharmaceuticals's stock-based compensation was $14.7M for fiscal 2025.
View full Aurinia Pharmaceuticals company overviewAurinia Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.7M | −$16.9M | −53.54% |
| 2024 | 2024-12-31 | $31.6M | −$13.7M | −30.27% |
| 2023 | 2023-12-31 | $45.3M | $13.0M | +40.28% |
| 2022 | 2022-12-31 | $32.3M | $1.1M | +3.38% |
| 2021 | 2021-12-31 | $31.2M | $13.8M | +79.00% |
| 2020 | 2020-12-31 | $17.5M | $10.0M | +135.42% |
| 2019 | 2019-12-31 | $7.4M | $554,000 | +8.08% |
| 2018 | 2018-12-31 | $6.9M | $2.6M | +61.72% |
| 2017 | 2017-12-31 | $4.2M | $2.9M | +206.72% |
| 2016 | 2016-12-31 | $1.4M | $0 | 0.00% |
| 2015 | 2015-12-31 | $1.4M | — | — |
Aurinia Pharmaceuticals quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.8M | −$2.6M | −47.81% |
| Q1 2026 | 2026-03-31 | −$866,000 | $2.5M | — |
| Q4 2025 | 2025-12-31 | $6.7M | −$2.2M | −24.79% |
| Q3 2025 | 2025-09-30 | $5.9M | −$2.4M | −28.92% |
| Q2 2025 | 2025-06-30 | $5.4M | −$3.1M | −36.64% |
| Q1 2025 | 2025-03-31 | −$3.4M | −$9.1M | — |
| Q4 2024 | 2024-12-31 | $8.9M | −$2.8M | −23.98% |
| Q3 2024 | 2024-09-30 | $8.3M | −$3.5M | −29.48% |
| Q2 2024 | 2024-06-30 | $8.6M | −$3.7M | −30.01% |
| Q1 2024 | 2024-03-31 | $5.7M | −$3.7M | −39.40% |
| Q4 2023 | 2023-12-31 | $11.8M | $4.9M | +70.50% |
| Q3 2023 | 2023-09-30 | $11.8M | $3.5M | +41.92% |
| Q2 2023 | 2023-06-30 | $12.3M | $2.2M | +22.01% |
| Q1 2023 | 2023-03-31 | $9.5M | $2.4M | +34.80% |
| Q4 2022 | 2022-12-31 | $6.9M | −$1.7M | −19.53% |
| Q3 2022 | 2022-09-30 | $8.3M | $1.2M | +17.32% |
| Q2 2022 | 2022-06-30 | $10.1M | $2.3M | +29.69% |
| Q1 2022 | 2022-03-31 | $7.0M | −$798,000 | −10.20% |
| Q4 2021 | 2021-12-31 | $8.6M | $3.4M | +66.71% |
| Q3 2021 | 2021-09-30 | $7.1M | $2.5M | +53.81% |
| Q2 2021 | 2021-06-30 | $7.8M | $3.6M | +84.51% |
| Q1 2021 | 2021-03-31 | $7.8M | $4.3M | +123.71% |
| Q4 2020 | 2020-12-31 | $5.1M | — | — |
| Q3 2020 | 2020-09-30 | $4.6M | — | — |
| Q2 2020 | 2020-06-30 | $4.2M | — | — |
| Q1 2020 | 2020-03-31 | $3.5M | — | — |
Aurinia Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Aurinia Pharmaceuticals's stock-based compensation decreased from $17.5M to $14.7M, a change of −$2.8M. The latest reported quarter, Q2 2026, shows $2.8M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals source filings ↗